|Articles|March 15, 2003

BioPharm International

  • BioPharm International-03-01-2003
  • Volume 16
  • Issue 3

Inside Washington: The Big Shift

Author(s)Jill Wechsler

Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 23 years ago

Biotech World: India Blossoms

almost 23 years ago

Outsourcing Outlook: One-Stop Shops

almost 23 years ago

Qualification of a Chromatographic Column: Why and How to Do It

almost 23 years ago

Guest Editorial: Recruiting Biotech Talent

almost 23 years ago

Survival Strategies: How to Purchase COTS Software

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!